select trial semaglutide nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis What the SELECT trial of

Start medication at low dose (semaglutide 0.25 mg weekly or tirzepatide 2.5 mg weekly)

Achieve Your Weight Loss Goals At Body by Barker, we know that maintaining a healthy weight is about much more than diet and exercise alone

A 2023 analysis comparing GLP-1 drugs found that triple-receptor agonists like retatrutide produced greater reductions in caloric intake in the first two weeks compared to single or dual receptor drugs

Additionally, patients with diabetic kidney disease or on certain blood pressure medications should work closely with providers to monitor kidney function and electrolytes

Dinh Tran suggests these strategies: For the Pill: Ensure you take it with exactly 4 ounces of water

Le troisime pilier, savoir l'agonisme du rcepteur du glucagon, est unique : il stimule l'oxydation lipidique hpatique et augmente la dpense nergtique, un effet absent chez les agonistes duaux